Several global drugmakers, including Pfizer, Roche and Bayer, have not met full mandatory disclosures of their patented medicines in India, making them vulnerable to penalties and potentially allowing local firms to make and sell low-cost version of their drugs, local patent lawyers said.

To ensure that the patents granted in India are being utilised for the benefit of patients, companies must